🇺🇸

US SEC Filing Intelligence

· daily

Contract Option Exercises — October 03, 2026

This digest covers two contract option exercises totaling $541.7 million, both civilian (NASA and GSA), with no defense-related awards. The dominant theme is sustained civilian agency investment in engineering and space transportation services, with SAIC ($287.4M cost-plus-fixed-fee) and Boeing ($254.3M firm-fixed-price) representing contrasting risk profiles. The highest-conviction signal is Boeing's long-duration NASA Commercial Crew Program commitment through 2027, offering predictable revenue but fixed-price execution risk. A key watch item is SAIC's high subaward ratio ($665M vs. $287.5M obligated), which may compress margins and warrants scrutiny of subcontractor dependencies.

2 total filings
· daily

Federal Professional Services Contracts — October 03, 2026

This digest covers a single, large civilian contract awarded to Science Applications International Corporation (SAIC) by the General Services Administration (GSA) for engineering services, valued at $287.4 million. The contract is entirely civilian (0% defense-related), cost-plus-fixed-fee in structure, and historical in nature, having ended in December 2022. The highest-conviction signal is neutral, reflecting the contract's low profit-risk profile but offset by a massive $665 million subaward total that suggests compressed margins and complex financial flows. Key risks include the contract's age (no current revenue contribution unless extended) and the potential for SAIC to be acting as a pass-through entity, limiting earnings quality. Investors should monitor for any follow-on awards under the same GSA vehicle and SAIC's broader reliance on cost-plus contracting.

1 total filings
· daily

NASA & Space Contracts Intelligence — October 03, 2026

This digest covers a single, large civilian NASA contract awarded to The Boeing Company valued at $254.3 million (with a potential $363.6 million including options), representing 100% of the period's total obligation. The contract, a firm-fixed-price delivery order under NASA's Commercial Crew Program, supports the design and certification of an integrated crew transportation system for ISS missions through May 2027. The highest-conviction signal is neutral, reflecting Boeing's entrenched competitive position in human spaceflight but tempered by fixed-price execution risk and a long performance period. A key risk is the potential for cost overruns on this fixed-price structure, which has historically challenged Boeing in similar NASA programs.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — October 03, 2026

This digest covers two mega contracts totaling $541.7 million, both awarded to civilian agencies (GSA and NASA) with zero defense-related obligations, signaling a non-DoD procurement focus for the period. The dominant theme is long-duration, high-value engineering and space transportation services, with SAIC ($287.4M) and Boeing ($254.3M) as the sole recipients. The highest-conviction signal is Boeing’s fixed-price NASA Commercial Crew contract, which provides predictable revenue through 2027 but carries medium execution risk due to fixed-price exposure. A key risk is SAIC’s historical cost-plus contract, which ended in 2022 and shows negative outlayed amounts, suggesting complex financial flows and no current revenue contribution. Investors should watch for any extensions or new awards under SAIC’s vehicle and monitor Boeing’s option exercises for post-certification missions.

2 total filings
· daily

High-Value Federal Grants ($5M+) — October 03, 2026

This digest covers two high-value federal grants totaling $541.7 million, both awarded to major defense contractors (SAIC and Boeing) but entirely under civilian agencies (GSA and NASA), reflecting zero defense exposure. The dominant theme is long-duration, high-certainty civilian space and engineering services programs, with Boeing’s $254.3 million NASA Commercial Crew contract (2015-2027) offering the highest-conviction signal of sustained revenue visibility despite fixed-price execution risk. The highest-conviction signal is Boeing’s firm-fixed-price structure, which provides predictable revenue but carries medium execution risk from potential cost overruns on crew transportation development. Key risk: SAIC’s $287.5 million GSA contract is historical (ended 2022), offering no current revenue contribution, and its high subaward ratio ($665M subawards vs. $287.5M obligation) signals compressed margins and complex financial flows that warrant caution on future similar awards.

2 total filings
· daily

General Federal Contracts — October 03, 2026

This digest covers two civilian agency contracts totaling $541.7 million, with no defense-related awards, highlighting a pure civilian-sector theme centered on NASA and GSA. The highest-conviction signal is Boeing’s $254.3 million firm-fixed-price NASA Commercial Crew contract (2015–2027), which offers long-term revenue visibility but carries medium execution risk due to fixed-price exposure. The SAIC $287.4 million GSA engineering services contract is historical (ended 2022), providing no current revenue contribution and flagged for complex financial flows. Key risks include Boeing’s fixed-price execution risk on a multi-year space program and SAIC’s compressed margins from high subaward pass-throughs. Investors should monitor NASA option exercises for Boeing and any GSA re-compete opportunities for SAIC.

2 total filings
· daily

All NASA Contracts — October 03, 2026

This digest covers a single NASA contract award to The Boeing Company valued at $254.3 million obligated, with a total potential value of $363.6 million including options, under NASA's Commercial Crew Program. The contract is entirely civilian, with no defense-related obligations, and spans from December 2015 to May 2027, reflecting long-term program stability. The highest-conviction signal is neutral, given the fixed-price structure and full-and-open competition, which provide revenue visibility but also execution risk. Key watch items include Boeing's ability to manage fixed-price risk and NASA's option exercise decisions for post-certification missions.

1 total filings
· daily

Biotech Small-Cap Approvals — October 02, 2026

The October 2, 2026 approval stream for biotech small-caps delivered 13 approvals, all classified as 'Other' with no NME, biosimilar, or label expansion designations per the provided data. The mix is heavily weighted toward neutral biosimilar-type approvals (7 neutral) and 6 bullish signals, with the highest-conviction events being three NME approvals: TIRATRICO (EMCITATE) from RARE THYROID THERAPEUTICS INTERNATIONAL AB, DENOSUMAB-ADET (DEGEVMA) from TEVA PHARMACEUTICALS, and ZILURGISERTIB (ATEBRIOZ) from INCYTE CORP, all carrying Priority Review and Orphan designations (except DENOSUMAB-ADET which lacks explicit designations). The dominant therapeutic theme is specialty/rare disease, with oncology and metabolic signals from INCYTE and TEVA, plus a rare thyroid entry. The highest-conviction signal is INCYTE's ZILURGISERTIB, an NME with Priority Review and Orphan status, indicating strong commercial potential in a niche oncology indication. Key risks include the lack of detailed commercial data (peak sales, exclusivity, pricing) across all approvals, and the potential for IRA negotiation exposure on small-molecule NMEs like ZILURGISERTIB and TIRATRICO, though timelines are not specified.

13 total filings
· daily

NME Blockbuster Approvals — October 02, 2026

During the period of October 2, 2026, the FDA approved two NMEs under Priority Review and Orphan Drug designations, signaling a bullish day for rare disease-focused sponsors. TIRATRICO (EMCITATE) from RARE THYROID THERAPEUTICS INTERNATIONAL AB and ZILURGISERTIB (ATEBRIOZ) from INCYTE CORP both received approvals, though neither was classified as a standard NME in the stream mix. The dominant therapeutic theme is rare disease specialization, with both drugs targeting narrow, high-unmet-need populations. The highest-conviction signal is INCYTE CORP’s approval of ZILURGISERTIB, reinforcing its oncology/hematology pipeline execution. Key risk: both approvals lack disclosed peak sales estimates and pricing details, creating commercial uncertainty despite strong regulatory signals.

2 total filings
· daily

Big Pharma Approvals — October 02, 2026

This period's FDA digest is dominated by a single, high-conviction NME approval for ABBVIE INC's TAVAPADON (JUVMO), a 'FALLBACK' type approval that signals a strategic pivot or new pipeline entry for the sponsor. With zero biosimilar or label expansion activity, the investment story is narrowly focused on ABBVIE's ability to commercialize a new molecular entity. The bullish signal (8/10 strength, 8/10 materiality) suggests significant commercial potential, though the lack of disclosed peak sales, exclusivity, or pricing data introduces uncertainty. The key risk is the opaque 'FALLBACK' designation, which may imply a contingency approval or a drug with a limited indication, requiring close monitoring of launch execution and payer reception.

1 total filings
· daily

Orphan Drug Approvals — October 02, 2026

The October 2, 2026 orphan drug approval digest features 3 approvals, all designated as 'Other' (non-NME, non-biosimilar, non-label expansion) but functionally representing 2 high-value New Molecular Entity (NME) approvals and 1 label expansion. The dominant therapeutic area is rare disease, with two NMEs—TIRATRICO (EMCITATE) from Rare Thyroid Therapeutics International AB and ZILURGISERTIB (ATEBRIOZ) from Incyte Corp—both receiving Priority Review and Orphan Drug designations, signaling strong unmet need and premium pricing potential. The highest-conviction signal is the dual NME approvals for Rare Thyroid Therapeutics and Incyte, each carrying 8/10 bullish signals and materiality, suggesting significant commercial opportunities in niche orphan markets. A key risk is the lack of disclosed peak sales estimates and exclusivity details, making precise revenue modeling impossible, while the label expansion for MAVACAMTEN (CAMZYOS) from Bristol-Myers Squibb provides incremental but lower-conviction upside.

3 total filings
· daily

New Drug Approvals (Original) — October 02, 2026

The October 2, 2026, FDA approval digest features 14 approvals, all classified as 'Other' (non-NME, non-biosimilar, non-label-expansion), with a 7/7 split between bullish and neutral signals. The period is dominated by generic/biosimilar-style approvals (MUPIROCIN CALCIUM, DEXMEDETOMIDINE, PREDNISOLONE ACETATE, METRONIDAZOLE, ESOMEPRAZOLE, NAFCILLIN) and label expansions (APIXABAN, DICLOFENAC), representing low-differentiation, commodity competition. The highest-conviction signals are the NME approvals: TIRATRICO (EMCITATE) from Rare Thyroid Therapeutics (Priority Review, Orphan), ZILURGISERTIB (ATEBRIOZ) from Incyte (Priority Review, Orphan), TAVAPADON (JUVMO) from AbbVie, and DENOSUMAB-ADET (DEGEVMA) from Teva—the latter two signal major commercial launches in high-value therapeutic categories. The key watch item is the lack of disclosed peak sales estimates or exclusivity data for all 14 drugs, limiting precise revenue forecasting; investors must monitor launch execution and payer dynamics, especially for the NMEs, where pricing power and market access are unquantified.

14 total filings
· daily

Defense Manufacturing Contracts — October 02, 2026

In the analyzed period, two contracts totaling $667.3 million were awarded exclusively by NASA to The Boeing Company under the Commercial Crew Program, with no defense-related obligations. The contracts, valued at $360.6 million and $306.7 million respectively, are firm-fixed-price delivery orders for crew transportation system design and certification, extending through 2028. The highest-conviction signal is Boeing's entrenched position in NASA's crewed spaceflight efforts, supported by full-and-open competition wins and substantial subaward activity. However, the fixed-price structure and long performance periods introduce execution risk, particularly around cost overruns and certification milestones.

2 total filings
· daily

New Federal Contractors — October 02, 2026

The two contracts analyzed, totaling $667.3 million, are both civilian NASA awards to The Boeing Company under the Commercial Crew Program, with zero defense-related content. The dominant theme is sustained government investment in commercial crew transportation to the ISS, with Boeing securing two firm-fixed-price delivery orders worth $360.6 million (awarded 2015) and $306.7 million (awarded 2016, with options up to $722.4 million). The highest-conviction signal is Boeing's entrenched competitive position in a program of national priority, though the fixed-price structure carries medium execution risk. Key watch items include NASA's exercise of options on the 2016 contract and Boeing's progress toward certification milestones, which could drive incremental revenue or reveal cost overruns.

2 total filings
· daily

Significant Contract Modifications ($10M+) — October 02, 2026

The two Boeing contracts from NASA's Commercial Crew Program total $667.3 million in obligations, both civilian and both awarded to Boeing under full-and-open competition. The combined awards underscore NASA's sustained commitment to commercial crew transportation to the ISS through at least 2028, with Boeing as the sole prime recipient in this digest. The highest-conviction signal is the $360.6 million firm-fixed-price delivery order (bullish, strength 7/10), which provides long-term revenue visibility but carries medium execution risk due to fixed-price cost overrun exposure. A key risk is the neutral-rated $306.7 million contract (strength 6/10) where options worth $722.4 million remain unexercised, creating upside uncertainty. Investors should monitor option exercises and Boeing's certification milestones for both contracts.

2 total filings
· daily

Contract Deobligations Alert — October 02, 2026

The two contracts analyzed, totaling $667.3 million, are both civilian NASA awards to The Boeing Company under the Commercial Crew Program, with zero defense-related content. The dominant theme is Boeing's entrenched position in crewed space transportation to the ISS, supported by two long-duration firm-fixed-price delivery orders spanning 2015-2028. The highest-conviction signal is the $360.6 million award (materiality 6/10, bullish), reflecting Boeing's competitive moat in a sole-source-like environment despite full-and-open competition. Key risks include fixed-price execution risk on both contracts and the potential for NASA to exercise or not exercise options on the $722.4 million potential value contract, which could materially alter Boeing's revenue stream. Investors should monitor Boeing's certification milestones and NASA's option exercise decisions, as these contracts provide stable but not high-growth revenue visibility.

2 total filings
· daily

Contract Option Exercises — October 02, 2026

Over a single day on October 2, 2026, Boeing secured $667.3 million in firm-fixed-price delivery orders from NASA’s Commercial Crew Program, both awarded under full-and-open competition. Both contracts are civilian (NASA), not defense-related, reinforcing the theme of sustained government investment in commercial crew transportation to the ISS through 2028. The highest-conviction signal is Boeing’s $360.6 million award, which provides long-term revenue visibility but carries medium execution risk due to the fixed-price structure. A key watch item is the exercise of options on the second contract, which could unlock an additional $416 million in potential value.

2 total filings
· daily

NASA & Space Contracts Intelligence — October 02, 2026

Over a single day, October 2, 2026, NASA awarded Boeing two firm-fixed-price delivery orders under the Commercial Crew Program totaling $667.3 million, with zero defense-related spending. Both contracts support the design, development, and certification of a crew transportation system to the ISS, with performance extending through 2028 and a combined potential value exceeding $1.1 billion including options. The highest-conviction signal is Boeing’s entrenched position in NASA’s priority ISS access program, but the fixed-price structure transfers cost overrun risk to Boeing, and the 11-year performance period introduces execution and milestone delay risk. Investors should monitor NASA’s exercise of options and Boeing’s certification progress for margin signals.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — October 02, 2026

The two contracts analyzed, totaling $667.3 million, are exclusively civilian awards from NASA to The Boeing Company under the Commercial Crew Program, with zero defense-related content. The dominant theme is Boeing’s entrenched role in crewed space transportation to the ISS, supported by two firm-fixed-price delivery orders with a combined potential value exceeding $1.08 billion when options are included. The highest-conviction signal is a bullish $360.6 million award (signal strength 7/10) that provides long-term revenue visibility through 2026, though the fixed-price structure carries execution risk. A key watch item is the $306.7 million contract’s option exercise timeline through 2028, which will determine whether Boeing realizes the full $722.4 million potential value. The absence of defense contracts underscores a pure civilian space exposure for Boeing in this digest, with no direct read-through to defense primes.

2 total filings
· daily

High-Value Federal Grants ($5M+) — October 02, 2026

The two contracts analyzed, totaling $667.3 million, are exclusively civilian awards from NASA to The Boeing Company under the Commercial Crew Program, representing zero defense exposure. The dominant theme is sustained government investment in crewed space transportation to the International Space Station (ISS), with Boeing securing two firm-fixed-price delivery orders that provide long-term revenue visibility through 2028. The highest-conviction signal is Boeing's $360.6 million award (bullish, 7/10 strength), reflecting its entrenched competitive position in a full-and-open competition. However, the fixed-price structure shifts execution risk to Boeing, and the aggregate $667.3 million obligation is modest relative to Boeing's $70B+ annual revenue, limiting near-term materiality. Key watch items include NASA's exercise of options on the $306.7 million contract (potential value up to $722.4 million) and Boeing's progress toward certification milestones, which could trigger cost overruns or delays.

2 total filings